- Home
- DSU vs SIGA Comparison
DSU vs SIGA Comparison
Compare DSU & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- SIGA
- Stock Information
- Founded
- DSU 1998
- SIGA 1995
- Country
- DSU United States
- SIGA United States
- Employees
- DSU N/A
- SIGA N/A
- Industry
- DSU Finance Companies
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- DSU Finance
- SIGA Health Care
- Exchange
- DSU Nasdaq
- SIGA Nasdaq
- Market Cap
- DSU 548.1M
- SIGA 594.3M
- IPO Year
- DSU N/A
- SIGA 1997
- Fundamental
- Price
- DSU $10.34
- SIGA $6.37
- Analyst Decision
- DSU
- SIGA
- Analyst Count
- DSU 0
- SIGA 0
- Target Price
- DSU N/A
- SIGA N/A
- AVG Volume (30 Days)
- DSU 148.2K
- SIGA 385.1K
- Earning Date
- DSU 01-01-0001
- SIGA 11-06-2025
- Dividend Yield
- DSU 10.06%
- SIGA 9.54%
- EPS Growth
- DSU N/A
- SIGA N/A
- EPS
- DSU N/A
- SIGA 1.03
- Revenue
- DSU N/A
- SIGA $172,249,641.00
- Revenue This Year
- DSU N/A
- SIGA N/A
- Revenue Next Year
- DSU N/A
- SIGA $115.06
- P/E Ratio
- DSU N/A
- SIGA $6.11
- Revenue Growth
- DSU N/A
- SIGA N/A
- 52 Week Low
- DSU $9.22
- SIGA $4.95
- 52 Week High
- DSU $11.40
- SIGA $9.62
- Technical
- Relative Strength Index (RSI)
- DSU 49.09
- SIGA 23.08
- Support Level
- DSU $10.29
- SIGA $6.20
- Resistance Level
- DSU $10.39
- SIGA $8.46
- Average True Range (ATR)
- DSU 0.06
- SIGA 0.31
- MACD
- DSU 0.01
- SIGA -0.22
- Stochastic Oscillator
- DSU 65.75
- SIGA 3.41
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.